Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorXijing Hospital
About this trial
Alzheimer's Disease (AD) is the primary cause of dementia, with its prominent feature being cognitive decline. The cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention. This study will be conducted to evaluate the efficacy and safety of cerebellar Intermittent theta-burst stimulation (CRB-iTBS) in participants with mild Alzheimer's disease on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 3 months of treatment in the Core Study. This project aims to provide a valid treatment to improve the cognitive function and quality of life for those with Alzheimer's disease.
Eligibility criteria
Qualifiers
Age: 50-85 years old
Meet the core clinical criteria of NIA-AA for possible Alzheimer's disease dementia, and PET or cerebrospinal fluid markers show elevated p-tau and decreased A β (1-42)
MMSE score ranges from 18-26 points; CDR score 0.5-1 points
The patient has received treatment with acetylcholinesterase inhibitors (AChEI), NMDA receptor antagonists, or mannequine therapy, and the current dosing regimen has remained stable for the 12 weeks prior to baseline assessment
Disqualifiers
Neurodegenerative disorders other than AD.
Significant intracranial focal or vascular pathology seen on brain MRI scan
History of seizure (with the exception of febrile seizures in childhood)
Major depressive disorder (current)
Trial design
Treatments tested in this trial
- Intermittent Theta-Burst Transcranial Magnetic Stimulation
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xijing Hospital
Lead sponsor
Tang-Du Hospital
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
Xi'an No.3 Hospital
Collaborator
Source ClinicalTrials.gov